Skip to Content

Diasorin SpA DSRLF

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics--testing done on samples taken from the human body, such as blood and issue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (62% of sales) and molecular diagnostics (29%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute the remaining 9% of total sales, DiaSorin has a strong presence in Europe, the Middle East, and Africa; the region accounts for the largest portion of company revenue (44%), followed by North America (41%), Asia-Pacific (11%), and Latin America (4%).

Via Crescentino Snc, Saluggia
Vercelli, 13040, Italy
T +39 1614871
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 2,066